Showing 2630 results
- https://www.novartis.com/stories/physician-scientist-donald-ganem-takes-reins-infectious-disease
- https://www.novartis.com/news/media-releases/novartis-announces-new-organizational-structure-accelerate-growth-strengthen-pipeline-and-increase-productivityAd hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of…
- https://www.novartis.com/stories/potential-weight-loss-treatment-takes-shape-help-from-patients
Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.
- https://www.novartis.com/news/media-releases/novartis-gibt-neue-organisationsstruktur-bekannt-fur-schnelleres-wachstum-eine-starkere-pipeline-und-hohere-produktivitatAd-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase…
- https://www.novartis.com/stories/predictive-analytics-could-bring-medicines-patients-faster
Novartis researchers are using data to accelerate drug development.
- https://www.novartis.com/stories/tackling-health-toll-climate-change
- https://www.novartis.com/stories/bringing-real-change-people
An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.
- https://www.novartis.com/news/media-releases/novartis-presents-new-four-year-data-efficacy-and-safety-kesimpta-ofatumumab-people-living-relapsing-multiple-sclerosisPhase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
- https://www.novartis.com/news/media-releases/novartis-expands-zolgensma-manufacturing-capacity-approval-multi-product-north-carolina-facilityClearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
- https://www.novartis.com/news/media-releases/fda-approves-novartis-vijoice-alpelisib-first-and-only-treatment-select-patients-pik3ca-related-overgrowth-spectrum-prosVijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page